Medicinal Chemistry News and Research

RSS

Study maps enzyme target for potential treatment of rare genetic disorder

Researchers at the Icahn School of Medicine at Mount Sinai have mapped an enzyme that could be targeted to develop new treatments for glutaric aciduria type 1 (GA1), a rare genetic disorder that can lead to brain damage, revealing new details about how the enzyme works and how its activity is controlled.

13 Nov 2026

New molecular approach shows promise against treatment-resistant prostate cancer

Many modern cancer drugs typically target a specific protein or signaling pathway to treat tumors.

11 Nov 2026

Five AI models tackled 227 pharmacy exam questions. Here's where they struggled

Researchers evaluated five large language models using 227 infectious disease-related pharmacy examination questions and found that all achieved approximately 90% accuracy, with ChatGPT-4o-mini scoring highest at 91.2%. Accuracy was significantly lower for medicinal chemistry, clinical microbiology, higher-order cognitive questions, and image-containing questions, raising concerns about relying on AI-generated answers without independent verification.

9 Nov 2026

IITGN research explores new approach to tackling drug-resistant glioblastoma

Cancer remains among the most deadly diseases worldwide. Globally, more than 300,000 new cases of brain cancer are reported each year, with glioblastoma, an aggressive form of brain cancer, accounting for over 250,000 deaths.

6 Nov 2026

Light-powered reaction gives discarded drug compounds new potential

Throughout the drug development process, which can take a decade or more, tens of thousands of chemical compounds are produced that never go on to become medicines.

6 Nov 2026

Insilico Medicine leader shares AI-driven drug discovery insights in Shanghai and Dubai

Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to attend the China Healthcare Summit in Shanghai. On the afternoon of November 3 at 16:45, she will deliver a keynote speech in the panel titled: "THE COMMODITIZATION TRAP: WHO WINS WHEN EVERYONE HAS THE SAME AI?"

30 Oct 2026

$8.2 million grant advances on-demand male contraceptive development

Weill Cornell Medicine has received a four-year, $8.2 million grant from the National Institute of Child Health and Human Development (NICHD) to develop and test an experimental on-demand male contraceptive pill that temporarily stops sperm in their tracks

22 Oct 2026

Researchers use AI to identify early-stage inhibitors for antiviral therapy

Viral infections can be difficult to treat as viruses evolve rapidly, allowing them to develop resistance to drugs designed to attack viral proteins directly.

19 Oct 2026

Concept Life Sciences appoints Dr Adrijana Vinter as Chief Executive Officer

We are pleased to announce the appointment of Dr Adrijana Vinter as Chief Executive Officer. Dr Vinter brings more than 20 years of experience spanning medicinal chemistry research, commercial development and executive leadership in the pharmaceutical and contract research industry sectors.

From Concept Life Sciences 13 Oct 2026

BioDuro appoints Greg Makara as Senior Vice President Lead Discovery Chemistry to strengthen early drug discovery capabilities

BioDuro, a global integrated contract research, development and manufacturing organization (CRDMO), today announced the appointment of Greg Makara, Ph.D., as Senior Vice President Lead Discovery Chemistry.

From BioDuro 5 Oct 2026

Kansas researchers secure NIH funding to fight antibiotic resistance

As antibiotic resistance makes everyday infections tougher to treat and emerging pathogens drive challenging infectious-disease outbreaks, researchers in Kansas from multiple disciplines and institutions are teaming up to target pathogens and overcome antibiotic resistance.

25 Sep 2026

New drug molecule reshapes protein to improve cancer target selectivity

A square peg doesn't fit a round hole. But what if the peg could change the shape of the hole?

16 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

LSD deconstruction reveals promising new drug candidates

University of California, Davis researchers have stripped down LSD to the base features responsible for its hallucinogenic and therapeutic effects.

7 Sep 2026

Researchers develop mild skeletal editing method for medicinal chemistry

Researchers at Ritsumeikan University report a halogen-guided method for transforming accessible hydroxycoumarins into coumaranones, valuable heterocyclic structures in medicinal chemistry.

27 Aug 2026

Dual-action compounds show promise against aggressive cancer and infections

Cancer patients often face more than the disease itself. Their treatment is frequently complicated by infections and other health conditions, meaning they may need to take several different medications at once.

18 Aug 2026

'Locked' cancer therapeutic safely shrinks breast tumors in mice

Although there are many cancer treatments available today that effectively eliminate abnormal cells, these therapies may also damage healthy cells, leading to unwanted side effects.

13 Aug 2026

Researchers find unexpected protein regulator of leukemia drug sensitivity

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

12 Aug 2026

Study identifies a novel direct drug target for head and neck squamous cell carcinoma

Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most common cancer type worldwide.

6 Aug 2026

Natural compounds could combat drug-resistant malaria and babesiosis

As parasites become increasingly resistant to existing drugs, researchers at the University of California, Riverside are working to develop a new generation of treatments for two serious infectious diseases: malaria and babesiosis.

31 Jul 2026